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Abstract Treatment of cells with cytokines and growth
factors leads to the synthesis of Suppressor of Cytokine
Signalling (SOCS) proteins that act as potent negative
regulators of signalling via the Jak/STAT pathway. We
used immunohistochemistry to identify cells and patholo-
gies where SOCS3 expression might influence acute and
chronic inflammatory responses in human tissues. Epitope
and GFP tagged SOCS3 fusion proteins were localised
predominantly in the nucleus of transfected cells and a
validated anti SOCS3 antiserum revealed the expression of
SOCS3 in the nucleus and cytoplasm of macrophages,
endothelial and epithelial cells in a wide range of normal
tissues in tissue microarrays (n = 31 different tissues).
Nuclear SOCS3 was only seen in cells expressing a high
level of the protein. Comparative immunostaining of acute,
chronically and granulomatously inflamed human tissues
revealed higher levels of nuclear and cytoplasmic SOCS3
expression in inflamed than in corresponding normal tis-
sues, particularly in recruited leukocyte populations, but
also in epithelia. The staining appeared more intense,
suggesting higher expression levels, in areas where
inflammation was more acute, consistent with the time
course of SOCS3 induction described in vitro. Expression
of SOCS3 protein by leucocytes and other cell types in
tissue sections could be a useful marker of cells undergoing
acute or chronic stimulation by cytokines in vivo.
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Introduction
The inflammatory response is driven by the release of
inflammatory mediators and the recruitment of circulating
leukocytes, which become activated at the site of inflam-
mation and release further mediators. Generally, the
inflammatory response is resolved by the release of
endogenous anti-inflammatory mediators and the accumu-
lation of intracellular negative regulatory factors (Nathan
2002). Failure to regulate inflammation adequately is
important in autoimmunity and infection and may play a
role in chronic diseases such as coronary artery disease,
obesity and cancer (Lin and Karin 2007). Anti-cytokine
therapies, such as anti-tumor necrosis factor-a, can suc-
cessfully treat some chronic inflammatory diseases (Feld-
mann and Maini 2003).
Suppressor of cytokine signalling (SOCS) proteins are
intracellular inhibitors of cytokine signalling that act in a
classical negative feedback loop (Croker et al. 2004).
SOCS3 may have profound effects on the regulation of
immunity and inflammation by affecting the activation,
development and homeostatic functions of all lineages
involved in immune and inflammatory responses (O’Shea
and Murray 2008). For example, SOCS3 limits the activi-
ties of the haematopoietic growth factors granulocyte
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colony stimulating factor (G-CSF) and granulocyte–mac-
rophage colony stimulating factor (GM-CSF) (Croker et al.
2004). Administration of G-CSF in vivo mimics emer-
gency granulopoiesis during infection. In SOCS3 condi-
tional knockout mice, this process is grossly exacerbated,
with neutrophil infiltration and destruction of liver, lung,
muscle and spinal tissue, resulting from increased intensity
and duration of G-CSF-induced Stat3 activation (Croker
et al. 2003; Kimura et al. 2004).
Stimulation of macrophages with lipopolysaccharide
(LPS) leads to the production of various cytokines
including IL-1, TGF-b, IL-10, and IL-6, all of which
upregulate SOCS3 expression (Dimitriou et al. 2008). Toll-
like receptor (TLR) stimulation can also upregulate SOCS3
expression independently of cytokine induction (Dalpke
et al. 2008). Indeed SOCS3 is one of the most abun-
dantly induced proteins in LPS-stimulated macrophages
(Yoshimura et al. 2007). SOCS3 then mediates feedback
inhibition of LPS-induced macrophage activation (Berlato
et al. 2002; Donnelly et al. 1999). SOCS3-transfected
murine macrophages produce reduced levels of LPS-
induced NO2
-, TNF-a, IL-6, and GM-CSF. The extent of
this inhibition is similar to that seen in wild type cells
treated with LPS and IL-10 (Berlato et al. 2002; Dimitriou
et al. 2008). Accordingly, primary peritoneal SOCS3-/-
macrophages exhibit impaired IL-10 regulation of
LPS-induced NO2
- and TNF-a (Berlato et al. 2002).
Macrophages from mice that lack SOCS3 expression in all
haematopoietic and endothelial lineages produce more IL-6
following IL-1 stimulation (Wong et al. 2006). SOCS3
mRNA is induced rapidly following cytokine stimulation,
being detectable within 20 min of IL-6 stimulation and
declining to basal levels after 8 h (Larsen and Ropke
2002). Notwithstanding, SOCS3 has also been shown to
positively regulate TLR4 signalling and M1 polarisation of
macrophages in mouse and rat (Wang et al. 2010; Liu et al.
2008a, b).
SOCS1 and SOCS3 exert their negative feedback via
several distinct mechanisms: (1) blocking JAK catalytic
domain-STAT protein substrate interactions to terminate
signal propagation; (2) competitively inhibiting JAK and
STAT binding to phosphotyrosine-based docking sites on
activated cytokine receptors, such as the shared cytokine
subunit gp130; (3) targeting their binding partners for
ubiquitination and proteasome degradation (Dimitriou
et al. 2008). The SOCS3 protein inhibits signal transduc-
tion via various receptors, including the IL-6R, IFN-cR,
GM-CSFR, IL-12 receptor b2, erythropoietin receptor,
IL-27Ra, IL-31Ra, G-CSF receptor, and leptin receptor
(Dimitriou et al. 2008; Dalpke et al. 2008; Xu et al. 2010).
However, SOCS3 does not bind or inhibit signalling via
the IL-10R, explaining the divergent activities of the pro-
inflammatory cytokine IL-6 and the immunoregulatory
cytokine IL-10 following TLR stimulation (Dimitriou et al.
2008; Yoshimura et al. 2007). Induction of SOCS has been
suggested as a means of immune evasion for bacteria, viruses
and parasites, for example Mycobacterium bovis BCG (Imai
et al. 2003; Dalpke et al. 2008). SOCS3 expression in den-
dritic cells (DCs) is important in regulating the production of
cytokines able to direct naı¨ve T-cell differentiation towards a
Th2 or a Treg phenotype (Li et al. 2006; Dimitriou et al. 2008).
Naı¨ve Th cells express high levels of SOCS3, which are
transiently decreased after antigenic stimulation, allowing
increased proliferation in response to IL-2. Both unstimu-
lated and stimulated Treg cells exhibit low SOCS3 levels
(Dimitriou et al. 2008). A negative regulatory role for
SOCS3 in IL-1 signalling has been observed in B-cells, in
which SOCS3 negatively regulates IL-1R signalling path-
ways (Dimitriou et al. 2008).
SOCS3 knockout leads to placental defects, possible
disturbances in intrahepatic erythropoiesis and embryonic
lethality (Roberts et al. 2001; Marine et al. 1999; Larsen
and Ropke 2002). Mice with a conditional deletion of the
Socs3 gene in haematopoietic and endothelial cells die as
young adults due to severe inflammatory lesions in the
peritoneal and pleural cavities (Croker et al. 2008).
Transgenic overexpression of SOCS3 also leads to
embryonic lethality, while SOCS3 overexpression in
T-cells leads to increased Th2 differentiation (Dalpke et al.
2008). SOCS3 mRNA expression has been identified in
foetal liver, primarily during the stage of fetal liver
erythropoiesis (Marine et al. 1999), and, at low levels, in
adult mouse spleen, thymus and lung (Starr et al. 1997). A
limited immunohistochemical study demonstrated SOCS3
expression in colonic epithelium and lamina propria leu-
cocytes in biopsies from normal individuals and ulcerative
colitis patients (Li et al. 2010).
The intracellular localisation of SOCS proteins has been
controversial, with most authors reporting only a cyto-
plasmic localisation (Ding et al. 2003), although Lee and
colleagues observed cytoplasmic and nuclear localisation
(Lee et al. 2008). Nuclear localisation, however, seems
inconsistent with SOCS proteins mediating their effects
solely at the cell membrane (Dimitriou et al. 2008; Ding
et al. 2003). To date detailed analysis of the expression
pattern and intracellular localisation of SOCS proteins in
human tissue samples has been limited by the availability
of specific anti-human SOCS3 antisera that work on for-
malin fixed tissue.
Here we report the subcellular localisation of SOCS3
fusion proteins in transfected cells and we validate an anti-
SOCS3 polyclonal rabbit serum and use it to determine the
expression pattern of SOCS3 protein in a wide range of
human tissues under normal and inflammatory conditions.
By means of immunohistochemistry (IHC), we demon-
strate both cytoplasmic and nuclear expression of SOCS3
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in vitro and in vivo. SOCS3 expression in tissue samples
may be a useful marker of cells undergoing acute and, to a
lesser extent, chronic cytokine stimulation in vivo.
Materials and methods
SOCS1 and SOCS3 fusion proteins
Human SOCS1 and SOCS3 coding sequences were
amplified by PCR and cloned into the expression plasmid
pcDNA3.1, together with the GFP gene. The coding region
of the recombinant plasmids was confirmed by DNA
sequencing.
IL-4 luciferase assay
Murine TARC luciferase reporter plasmids, SOCS expres-
sion vectors and hCMV b-galactosidase plasmids were
co-transfected into sub-confluent CHO cells using
Genejuice (Merck) in serum free Optimem medium
(InVitrogen) (Liddiard et al. 2006). After 18 h, cells were
stimulated with 20 ng ml-1 Interleukin-4 (R&D Systems) for
6 h. Whole cell extracts were prepared in Reporter Lysis
Buffer (Promega) and luciferase enzyme activity was deter-
mined using the Promega luciferase assay kit and b-galacto-
sidase enzyme activity in the same lysates was assayed by
measuring conversion of the colorimetric substrate chloro-
phenol red-b-D-galactopyranoside (Boeringer Mannheim) at
550 nm as described previously (Liddiard et al. 2006).
Preparation of transfectants and western blot
HEK293T cells were seeded into a six well plate and
transfected with GFP, SOCS2 or SOCS3 expression plas-
mids using Genejuice (Merck). Total cell lysates were
prepared 36 h post transfection and western blots per-
formed. Total protein (40 lg) was resolved on an SDS–
PAGE gel and western blotted onto nitrocellulose (in
duplicate). The blot was incubated with rabbit polyclonal
anti-SOCS3 sera (ab16030 and ab53984) (ABCAM,
Cambridge, UK) and bands detected with goat anti-rabbit
horseradish peroxidase (HRP) (Biorad) and chemilumi-
nescence (SuperSignal West Pico, Pierce). The blot was
stripped and re-probed with rabbit anti-tubulin polyclonal
antiserum (Cell Signaling Technology) to demonstrate
equal protein loading in all lanes.
Preparation of transfected paraffin wax cell blocks
Cell blocks of HEK293 cells transiently transfected with
SOCS2, SOCS3 or GFP were prepared using the Shandon
Cytoblock Cell Preparation System (Thermo Fisher
Scientific, Massachusetts, USA) as per the manufacturer’s
instructions and fixed in 4% formalin, followed by pro-
cessing following standard histological techniques.
Lipopolysaccharide stimulation and immunofluorescent
staining of human peripheral blood mononuclear cells
Human PBMCs were isolated from buffy coat preparations
(National Blood Service, London, UK) using Ficoll-Paque
plus according to manufacturer’s instructions (GE Health-
care, Little Chalfont, UK). Cells were plated in 8 well
LabTek chamber slides (Nunc, Rochester NY) and cultured
in X-Vivo 10 medium (Lonza, Wokingham, UK) plus 1%
autologous serum for 7 days. Cells were stimulated for 4 h
with 100 ng/ml LPS from Escherichia coli strain 055:B5
(Sigma–Aldrich, Gillingham, UK). After 4 h, medium was
removed, cells were fixed in 4% paraformaldehyde for
15 min then permeabilised for 5 min in 0.25% Triton
X-100/PBS. Non-specific binding was blocked for 30 min
with blocking solution (PBS/0.1% Triton X-100/1% BSA/
200 lg/ml human IgG). Anti-SOCS3 antibody (1:50 dilu-
tion, ab53984, Abcam) or isotype control (rabbit IgG,
Jackson Immunoresearch) was added and cells stained
overnight at 4C. PE conjugated secondary antibody (1:200
dilution, goat anti-rabbit IgG, Jackson Immunoresearch)
was added for 2 h at room temperature. Nuclei were
counterstained for 5 min with DAPI (Sigma–Aldrich).
Slides mounted with fluorescent mounting medium
(Sigma–Aldrich). Images were captured using a Zeiss 510
META confocal microscope.
Histological samples
All tissue samples were obtained with full ethical approval
from the National Research and Ethics Service (REC ref-
erence 04/Q1604/21). A wide range of normal human tis-
sues (n = 31) were obtained from the Cellular Pathology
Department, John Radcliffe Hospital, Oxford, UK, and
used to construct tissue microarrays (core diameter 1 mm),
using the MTA-1 manual arrayer (Beecher Instruments,
Wisconsin, USA). Two cores from each donor block were
taken to increase the sample area. Whole sections of tissue
were similarly obtained.
Antibodies and immunostaining
The following primary antibodies were used: rabbit poly-
clonal against SOCS3 (ab53984, ABCAM, Cambridge, UK)
and myeloperoxidase (AO398, Dako, Ely, UK); mouse
monoclonal antibodies against DC-SIGN (clone DC28,
R&D Systems, Minneapolis, USA); CD3 (clone LN10) and
CD56 (clone 1B6, Leica Biosystems Newcastle Ltd, New-
castle, UK); mouse monoclonal antibodies against CD20
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(clone L26), CD31 (clone JC70), CD61 (Y2/51), CD68
(clone PGM1) and glycophorin C (clone ret40f) were kindly
donated by Prof. K. Gatter, Nuffield Department of Clinical
Laboratory Sciences, Oxford, UK. Immunostaining was
performed using standard techniques and a Bond MaxTM
immunostaining machine (Leica Biosystems Newcastle Ltd,
Newcastle, U.K.). Heat mediated antigen retrieval was per-
formed on all tissue sections using the high pH Epitope
Retrieval 2 solution (Leica Microsystems, Wetzlar, Ger-
many) for 20 min at 100C. This was followed by a 5 min
peroxidase block as per the manufacturers’ kit and instruc-
tions (Leica Microsystems, Wetzlar, Germany). For single
labelled immunohistochemisty, the peroxidase/DAB
BondTM Polymer Refine Detection System (Leica Micro-
systems, Wetzlar, Germany) was used for visualisation. For
double labelled immunohistochemisty, the peroxidase/DAB
BondTM Polymer Refine Detection System and alkaline
phosphatase/fast red BondTM Polymer AP Red Detection
System (Leica Microsystems, Wetzlar, Germany) were used
for visualisation. All slides were counterstained using
Mayer’s haematoxylin and mounted in DePeX (VWR
International, Lutterworth, UK). As a negative control for the
anti-SOCS3 antiserum, a section was immunostained with
normal rabbit serum at an equivalent concentration
(0.0013 mg/ml).
Cell counting
Four 209 microscope fields were selected for counting for
each tissue sample. Three full sections of each condition
and corresponding normal tissue were used. The same
areas were marked and counted on each slide.
Statistical analysis
The Minitab 15 statistics package (Minitab, State Col-
lege, PA, USA) was used for all statistical analyses. Results
from cell population counts were converted to proportions
and recorded as a percentage e.g. percentage of CD68?
cells expressing SOCS3. Analysis of correlation was per-
formed using the non-parametric Spearman’s rank corre-
lation coefficient (r). This was achieved by performing a
Pearson correlation coefficient on ranked data. To identify
differences in population medians the Mann–Whitney U
test was used.
Results
Antibody validation
To establish the specificity of the SOCS3 antibodies we
performed western blots of GFP, SOCS2 and SOCS3
transfected cell lysates. Incubation with anti-SOCS3
ab53984 detected a single band of the correct molecular
weight in SOCS3 transfected cell lysate and this band was
not detected in lysates prepared from GFP or SOCS2
transfected cells (Fig. 1a, upper panel). Stripping the blots
and re-probing with an anti-tubulin antibody demonstrated
equal protein loading in each lane (Fig. 1a, middle panel).
SOCS3 was not detected with a second commercially
available SOCS3 antiserum (Fig. 1a, lower panel). Single
labelled immunohistochemistry (IHC) using the anti-
SOCS3 antibody ab53984 demonstrated positive staining
in the SOCS3 CHO cell transfectants in formalin fixed
paraffin blocks but did not identify protein expression in
the GFP or SOCS2 CHO cell transfectants (Fig. 1b), thus
confirming the specificity of the antibody. Of note immu-
nohistochemical staining showed that SOCS3 protein was
detectable in both the nuclear and cytoplasmic compart-
ments of transfected cells. To characterise the antiserum
further, immunohistochemical staining of formalin fixed
paraffin embedded human tonsil tissue was undertaken,
using rabbit serum as a negative control. Positive cyto-
plasmic and nuclear staining of a range of mononuclear
cells was seen with the anti-SOCS3 serum (Fig. 1c,upper
panel), but not with normal rabbit serum (Fig. 1c, lower
panel). Similarly, immunofluorescent staining of lipopoly-
saccharide (LPS) stimulated peripheral blood mononuclear
cells showed strong, predominantly nuclear staining
(Fig. 1d, upper panel), while no staining was seen with an
isotype control antibody (Fig. 1d, lower panel).
Fig. 1 Detection of SOCS3 protein in transiently transfected cells.
a Lysates prepared from HEK 293 cells transiently transfected with
pcDNA3.1 or the indicated SOCS expression vectors were fraction-
ated by SDS PAGE and transferred to HyBond membrane. Anti-
SOCS3 antisera (ab53984 and ab16030) were used for western
blotting at 1/1000 dilution and an anti-rabbit IgG HRP antibody was
used at 1/2000 dilution as secondary antibody. b Transiently trans-
fected 293 cells were harvested and fixed with 4% formalin before
embedding and sectioning for IHC with anti SOCS3 antiserum
ab53984 as described in ‘‘Methods and materials’’, 293 cells were
transfected with SOCS3, GPF, or SOCS2 (409 magnification).
c Normal tonsil immunostained for SOCS3 using rabbit polyclonal
antiserum ab53984 at a final concentration of 0.0013 mg/ml (upper
panel) compared with a negative control of normal tonsil immuno-
stained with normal rabbit serum at the same concentration (lower
panel). Scale bar (lower right) pertains to both panels and represents
50 lm. Panel D: SOCS3 is expressed in both the cytoplasm and
nucleus of primary human macrophages stimulated with lipopolysac-
charide (LPS). PBMCs (cultured for seven days) were stimulated with
100 ng/ml LPS for 4 h. Cells were fixed, permeabilised and stained
with anti-SOCS3 antibody (upper panel) or isotype control (lower
panel) followed by goat anti-rabbit PE-conjugated secondary anti-
body. Nuclei were counterstained with DAPI. Cells with compact,
unstained nuclei are lymphocytes. Data are representative of two
independent donors
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Sub-cellular localisation of SOCS1 and SOCS3
in transfected CHO cells
In order to study the sub-cellular localisation of SOCS3 in
living cells we transiently transfected CHO cells with
SOCS1-GFP and SOCS3-GFP fusion proteins and
observed them using confocal microscopy. Figure 2 shows
the distribution of GFP alone, SOCS1-GFP and SOCS3-
GFP in transfected CHO cells. GFP staining was distrib-
uted throughout the cell localising in both the nucleus and
cytoplasm (Fig. 2a). SOCS1-GFP and SOCS3-GFP were
localised predominantly in the nucleus, but were also
present to a lesser extent in the cytoplasm (Fig. 2b, c). No
fluorescence was detected in non-transfected cells (data not
shown). We tested whether the presence of the GFP-tag
would inhibit the ability of the SOCS protein to inhibit Jak/
STAT signalling using the IL-4 inducible murine TARC
promoter in transiently transfected CHO cells. As shown in
Fig. 3, the presence of the GFP tag does not affect the
ability of the SOCS1 or SOCS3 proteins to inhibit IL-4
signalling. However, we cannot state categorically that the
presence of the GFP-tag does not alter other properties of
the SOCS proteins, including subcellular localisation.
SOCS3 Immunohistochemistry on normal human tissue
In normal human tissues, SOCS3 immunopositivity was
widespread with varying intensity. Cells with lower levels
of expression demonstrated exclusively cytoplasmic
SOCS3 expression, while appreciable levels of nuclear
SOCS3 were visible in cells with higher cytoplasmic
expression levels. SOCS3 expression could be seen in
endothelial cells, macrophages, DCs, lymphocytes, neu-
trophils and in various epithelial cells in a wide range of
normal human tissues, including tonsil, skin, testis
(Fig. 4a), cervix, endometrium, fallopian tube (Fig. 4b),
kidney, small and large intestine and lung (Table 1, Fig. 4).
Epithelia that did not express SOCS3 included salivary
gland, oesophagus, stomach pancreas, liver, adrenal,
parathyroid and ovary. None of these tissues contained
constitutive lymphoid infiltrates or significant numbers of
other leucocytes. SOCS3 protein showed an interesting
distribution in lymphoid tissue, including spleen, lymph
node, tonsil and the small and large intestinal lamina pro-
pria. Strong immunopositivity was seen in tingible body
macrophages, interdigitating DCs and endothelial cells in
sinuses and germinal centre B lymphocytes. B lymphocytes
in the mantle and marginal zone showed little SOCS3
expression, as did paracortical T lymphocytes. In the thy-
mus, cells mediating positive and negative selection, such
as macrophages, DCs and epithelial cells, showed strong
SOCS3 immunopositivity, while thymocytes were largely
SOCS3-negative.
Double labelled immunohistochemistry confirmed
SOCS3 expression in CD68? macrophages/DCs (Fig. 4d),
DC-SIGN? DCs (Fig. 4e), and CD31? endothelial cells
(Fig. 4f). SOCS3 was also expressed by some CD3-posi-
tive T-lymphocytes, some CD20-positive B-lymphocytes
and occasional CD56-positive natural killer cells in normal
tissues (Table 1 and data not shown). The lymphocytes,
macrophages, DCs and endothelial cells showed a very
variable pattern of SOCS3 expression, ranging from no
expression to strong expression with variable cytoplasmic/
nuclear distribution. In general, judging expression levels
by immunohistochemical staining intensity, cells demon-
strating nuclear expression of SOCS3 protein had higher
cytoplasmic SOCS3 expression levels.
In bone marrow (Fig. 4c), strong SOCS3 immuno-
staining was seen in macrophages/DCs and in maturing
cells of myeloid lineage with features of monocytic or
granulocytic (neutrophil or eosinophil) differentiation, in
addition to patchy weaker immunopositivity in some
megakaryocytes and endothelial cells (Fig. 4). The identity
of the cells was confirmed by double immunostaining for
myeloperoxidase, glycophorin C and CD61 (data not
shown). Cells of myeloid, macrophage and endothelial cell
lineage expressed high levels of SOCS3 in both a cyto-
plasmic and nuclear location, while megakaryocytes
expressed intermediate levels of SOCS3 with none being
present in the nuclei. Cells of erythroid lineage expressed
very little SOCS3 and showed no nuclear staining.
SOCS3 expression in inflamed human tissues
We examined SOCS3 expression in acute, chronic and
granulomatous inflammatory conditions (Fig. 5, Table 2).
SOCS3 expression was seen in the majority of leucocytes,
particularly neutrophils, macrophages and lymphocytes, in
inflammatory lesions, regardless of the phenotype of the
inflammation. However, SOCS3 immunostaining appeared
to be most intense in areas of acute inflammation, e.g.,
acute appendicitis (Fig. 5a), acutely inflamed radicular
cysts, in crypt abscesses in ulcerative colitis (Fig. 5b),
adjacent to deep fissuring ulcers and in endothelial cells
and circulating neutrophils in Crohn’s disease (Fig. 5c),
and in the central but not the peripheral parts of granulomas
in various conditions (Fig. 5d–f). In these conditions, the
Fig. 2 Localisation of SOCS1 and SOCS3 in transfected CHO cells
using confocal microscopy. Plasmids encoding GFP-alone (a),
SOCS1-GFP (b), and SOCS3-GFP (c) were transiently transfected
into CHO cells grown on glass coverslips in 24 well plates using
GeneJuice. 24 h post-transfection the coverslips were removed,
washed in PBS, fixed using 4% paraformaldehyde and observed
using confocal microscopy. Fluorescence images are on the left and
phase contrast images on the right. Results are representative of three
independent experiments
c
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cells expressing high levels of SOCS3 appeared to be
predominantly neutrophils, together with a smaller number
of macrophages and other leucocytes. A higher level of
SOCS3 expression than that of the corresponding normal
tissue could also be seen in some epithelial and endothelial
cells adjacent to areas of intense acute inflammation, for
example crypt abscesses of ulcerative colitis (Fig. 5b) and
inflamed radicular cysts.
In order to investigate the effects of inflammation on
expression of SOCS3 by macrophages and DCs, the per-
centage of CD68? cells (macrophages/DCs) that expressed
SOCS3 was determined in four 209 representative
microscope fields in 3 cases of each of 7 pathological
conditions with acute, chronic or granulomatous inflam-
mation and compared with results for corresponding nor-
mal tissue. Each individual inflammatory condition
demonstrated a higher percentage of CD68? cells
expressing SOCS3 than the corresponding normal tissue,
with a significant p value in the majority of cases (Table 2).
Discussion
In this study, we have used GFP-tagged forms of the
human SOCS3 protein both to validate anti-SOCS3 anti-
sera and investigate the subcellular localisation of SOCS3
protein. We demonstrate, by means of transfection immu-
nohistochemical studies and immunofluorescent staining of
LPS-stimulated peripheral blood mononuclear cells, that
SOCS3 protein may be present in both the nucleus and
cytoplasm, in keeping with a previous study using SOCS3
transfectants (Lee et al. 2008). In vivo, we show that
nuclear SOCS3 immunostaining is seen only in cells with
high levels of cytoplasmic expression, consistent with in
vitro data demonstrating SOCS3 nuclear translocation only
when its levels increase (Lee et al. 2008). The transfectants
used in our study are likely to overexpress SOCS3,
explaining the observed, predominantly nuclear localisa-
tion of the GFP-tagged SOCS3 protein in these experi-
ments. There has been one previous limited
immunohistochemical study of SOCS3 expression in
human intestine (Li et al. 2010). While Li et al. describe
cytoplasmic expression of SOCS3(Li et al. 2010), close
examination of their immunohistochemical figures shows a
predominantly cytoplasmic distribution in epithelial cells,
but demonstrates a cytoplasmic and nuclear distribution of
SOCS3 in leucocytes with morphological appearances of
macrophages, DCs or lymphocytes in the large intestinal
lamina propria, in agreement with our data.
Previous studies using mRNA analysis identified
SOCS3 mRNA in normal mouse thymus, lung, spleen
Fig. 3 TARC-luciferase assay in CHO cells showing that SOCS1-
GFP and SOCS3-GFP are functional. CHO cells (2 9 106) were
transiently transfected with 500 ng mTARC-luciferase, 100 ng
hCMV b-galactosidase, 200 ng STAT6 and 200 ng of the indicated
SOCS expression vector. Cells were transiently transfected for 18 h
then stimulated with IL-4 (20 ng ml-1) for 6 h before harvest in
luciferase lysis buffer (Promega). Results are expressed as luciferase
activity normalized for beta galactosidase activity and are represen-
tative of three independent experiments and data are presented as
mean ± SEM
Fig. 4 SOCS3 expression in normal human tissues. a–c show single
immunostaining using the peroxidase technique (brown), while d–
f show double immunostaining with SOCS3 detection by the
peroxidase technique (brown) and detection of other antigens by the
alkaline phosphatase technique (red). a Testicular tubules (TUB)
showing strong cytoplasmic and weaker nuclear SOCS3 immunop-
ositivity, together with weaker immunopositivity in adjacent macro-
phages (MAC). b Fallopian tube epithelium (EP) showing strong
cytoplasmic and weaker nuclear SOCS-immunopositivity. c Bone
marrow showing strong cytoplasmic and nuclear SOCS3 immunop-
ositivity in cells of myeloid lineage (MYEL) including monocytes
and neutrophils and their precursors, weak cytoplasmic immunopo-
sitivity in megakaryoctes (see Fig. 5h) and minimal immunopositivity
in cells of erythroid lineage (ERY). d Small intestinal mucosa
immunostained for SOCS3 (brown) and CD68 (red) demonstrating
nuclear and cytoplasmic SOCS3 expression in some macrophages/
dendritic cells (arrows), in addition to SOCS3 immunopositivity in
epithelium (EP) and a range of other leucocytes. e Lymph node
immunostained for SOCS3 (brown) and DC-SIGN (red) demonstrat-
ing strong nuclear and weaker cytoplasmic SOCS3 immunopositivity
(arrows) in interdigitating dendritic cells in the paracortex. Various
lymphocytes and macrophages also show strong nuclear SOCS3
immunopositivity (arrowheads). f Duodenal submucosal vascular/
lymphatic channels demonstrating strong nuclear and cytoplasmic
SOCS3 immunopositivity (brown, arrows) in CD31-positive (red)
endothelial cells. Scale bars (bottom right of a–f) represent 50 m.
g. Magnified view of b to demonstrate cells with cytoplasmic staining
only (arrowheads) compared with those with both nuclear and
cytoplasmic staining (arrows). h Magnified view of c to demonstrate
a megakaryocyte with cytoplasmic staining only (arrowhead) com-
pared with myeloid cells showing both nuclear and cytoplasmic
staining (arrows). Scale bars (bottom right of a–f) represent 15 m.
(Color figure online)
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(Starr et al. 1997) and foetal liver (Marine et al. 1999), and
in human T-cells, monocytes and macrophages in vitro
(Isomaki et al. 2007; Rakshit et al. 2006). Using immu-
nohistochemistry we were able not only to confirm the
expression of SOCS3 protein in normal human adult thy-
mus, lung, liver and spleen, but also to identify the major
positive cell types as macrophages, immature myeloid DCs
and endothelial cells. Additionally, in normal tissues,
SOCS3 is expressed by neutrophils, some B and T-lym-
phocytes, occasional natural killer cells and many types of
epithelium. Our demonstration of SOCS3 expression by
epithelia at a number of sites is also in keeping with the
study by Li et al. in which the authors show expression of
SOCS3 by colonic epithelial cells (Li et al. 2010). The
figures in their study demonstrate SOCS3 expression by
lamina propria leucocytes with morphological appearances
suggesting that they might be macrophages, DCs or lym-
phocytes, although the authors do not comment on
expression by these cell types or determine their identity.
However, the SOCS3 expression pattern is consistent with
the pattern we describe here, both in normal colon and in
ulcerative colitis.
While epithelia adjacent to lymphoid aggregates or
leucocytic infiltrates (e.g., small and large intestine, tonsil,
cervix) express SOCS3, epithelia with few adjacent leu-
cocytes are generally SOCS3 negative, e.g., salivary gland,
oesophagus, stomach, pancreas and liver. Many epithelia
express cytokine receptors, for example for TNF-a, IL-1
and IL-6 (Fritz et al. 2008), which are known to induce
SOCS3. Epithelia adjacent to lymphoid aggregates or
leucocytic infiltrates may be subject to repeated stimula-
tion by these cytokines, leading to the induction of SOCS3
expression detectable by IHC.
SOCS3 shows an interesting distribution in lymphoid
tissue, including spleen, lymph node, tonsil and the small
and large intestinal lamina propria. Strong immunoposi-
tivity is seen in tingible body macrophages, interdigitating
DCs, DCs in sinuses and germinal centre B lymphocytes.
Mantle/marginal zone B and paracortical T lymphocytes
show little SOCS3 expression. Data from mouse studies
indicate only very low levels of SOCS3 expression in
progenitor B cells with a gradual increase in SOCS3 levels
as B cells become more mature (Le et al. 2007). SOCS3
can inhibit focal adhesion kinase activation, preventing B
cell adhesion to VCAM-1, increasing B-cell motility (Le
et al. 2007). It is likely that germinal centre B-cells require
significant motility to allow interaction with follicular DCs
and T-cells. Mantle/marginal zone B-cells may remain in
lymphoid areas for longer periods, thus requiring less
motility and possibly explaining their lower levels of
SOCS3 expression. An alternative explanation is discrep-
ancies between the human and mouse immune systems in
patterns of SOCS3 expression. Our observation of minimalT
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expression of SOCS3 by paracortical T-lymphocytes
appears incongruous with the observation in vitro that
naı¨ve Th cells express high levels of SOCS3, which are
transiently decreased after antigenic stimulation, allowing
increased proliferation in response to IL-2 (Dimitriou et al.
2008). One possibility is that the lymphoid tissue we
examined contained predominantly T lymphocytes
responding to antigen and thus undergoing activation/pro-
liferation, with concomitantly decreased SOCS3 levels.
Alternatively, there may be differences between the mouse
immune system, in which much previous work has been
done (Dimitriou et al. 2008), and the human immune
system.
In the thymus, cells mediating positive and negative
selection, such as macrophages, DCs and epithelial cells,
showed high levels of SOCS3 expression. Little expression
was seen in thymocytes, in keeping with a report showing
that SOCS3 conditional knockout mice demonstrate nor-
mal T-cell development in the thymus, suggesting SOCS3
may not play a crucial role in thymocytes (Chen et al.
2006).
Cells expressing SOCS3 in normal tissues may be sub-
ject to cytokine stimulation. At sites where few cytokines
are likely to be present, there may be some other, as yet
undetermined mechanism of SOCS3 induction causing
regulation of cytokine or TLR-mediated activation, possi-
bly to prevent inappropriate induction of an inflammatory
or immune response. Tissue macrophages or DCs may, for
example, express SOCS3 to prevent them producing pro-
inflammatory/immune cytokines and/or expressing crucial
co-stimulatory molecules that might otherwise induce an
immune or inflammatory response, with the inherent risks
of breaking immunological tolerance or causing inflam-
matory damage (Hart 1997). Similarly, certain endothelia,
particularly lymph node sinus endothelium and possibly
some small blood vessel endothelium, may present antigen
to lymphocytes to induce immunological tolerance (Soil-
leux et al. 2002). SOCS3 may be important at these sites in
preventing the production of pro-inflammatory/immune
cytokines. If such cells did present antigen to T lympho-
cytes, they might induce tolerance rather than immunity in
these lymphocytes.
In bone marrow, cells of the granulocytic and monocytic
lineage express high levels of SOCS3 (Fig. 4c), in keeping
with data from SOCS3 conditional knockout mice dem-
onstrating that SOCS3 is necessary to limit the activities of
the haematopoietic growth factors G-CSF and GM-CSF
(Croker et al. 2004; Croker et al. 2003; Kimura et al. 2004).
Expression of SOCS3 by myeloid cells may also explain
the appreciable levels of SOCS3 mRNA previously
detected in foetal liver (Marine et al. 1999). Mutations in
the tyrosine kinase JAK2 are identified in the majority of
patients with myeloproliferative neoplasms, such as
essential thrombocythaemia, a chronic proliferative neo-
plasm of megakaryocytes. JAK2, particularly when con-
stitutively activated by mutation, phosphorylates a tyrosine
residue in SOCS3 to inactivate it and escape its inhibition
(Elliott et al. 2009; Hookham et al. 2007). Our demon-
stration for the first time of SOCS3 expression by normal
megakaryocytes provides additional evidence for this
mechanism.
In keeping with our data showing high levels of SOCS3
expression in LPS-stimulated peripheral blood mononu-
clear cells, particularly cells morphologically resembling
macrophages, we observed a marked increase in SOCS3
expression in inflamed tissues, in many types of leucocyte,
particularly neutrophils, macrophages and lymphocytes, as
well as in epithelia, endothelia and fibroblasts. Given our
observation of high levels of SOCS3 expression in
maturing myeloid cells in bone marrow, it is not possible to
determine whether there is rapid induction of neutrophil
SOCS3 expression at sites of inflammation following their
recruitment to these sites or whether neutrophils that con-
stitutively express SOCS3 are recruited to the inflamed site.
Our striking observation of the significant accentuation of
SOCS3 expression in the centre of granulomas compared
with the peripheral parts. It is likely that there is both a
higher level of cytokines, such as IL-6, and of microbial
products at the centre of the granuloma, causing increased
levels of SOCS3 induction via both cytokine receptors and
TLRs. The relatively short half-life of SOCS3 would mean
that its expression relied on repeated or continuous
induction, mirroring local cytokine or microbial product
levels. Following IL-6 stimulation of myeloid cell lines,
mRNA from SOCS-3 is detectable within 20 min,
Fig. 5 SOCS3 expression in inflamed human tissues. All panels show
double immunostaining with SOCS3 detection by the peroxidase
technique (brown) and CD68 detection by the alkaline phosphatase
technique (red). a. Acute inflammation in acute appendicitis shows
moderate to strong SOCS3 immunopositivity in CD68? cells
(arrows) and strong SOCS3 immunopositivity in a range of other
leucocytes, particularly neutrophils (arrowheads). b In the colon in
ulcerative colitis, high levels of nuclear and cytoplasmic SOCS3
immunopositivity were seen in neutrophils in crypt abscesses
(arrowheads), as well as in epithelium adjacent to areas of acute
inflammation (EP). A small focus of surface ulceration is shown and
the underlying macrophages/dendritic cells (MAC) show strong
SOCS3 expression. c Submucosal blood vessel in Crohn’s disease
containing abundant SOCS3? neutrophils (arrows) and showing
strong endothelial SOCS3 expression, with adjacent SOCS3? mac-
rophages/dendritic cells (arrowheads). d Giant cell (arrow) from the
submucosa in colonic Crohn’s disease, showing strong nuclear and
weaker cytoplasmic SOCS3 immunopositivity, together with macro-
phages/dendritic cells (arrowheads) showing similar SOCS3 expres-
sion. e Non-necrotising granulomas of sarcoidosis (one granuloma is
circled) in which macrophages show moderate nuclear and cytoplas-
mic SOCS3 immunopositivity with marked accentuation in the centre
of the granuloma (arrow). f Granuloma in temporal arteritis showing
similar features to e. All scale bars (bottom right of each panel) 50 m.
(Color figure online)
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declining to basal levels after 8 h (Larsen and Ropke
2002). Our observation of more intense immunostaining,
suggesting higher SOCS3 expression levels, in acute than
chronic or granulomatous inflammation is also consistent
with the time course of SOCS3 induction, as well as pos-
sibly being related to higher cytokine levels in acute
inflammation.
In summary, we have demonstrated both cytoplasmic
and nuclear localisation of the regulatory protein SOCS3
and have performed the first detailed expression study on
SOCS3 by means of immunohistochemistry on human
tissues. Commensurate with its induction by a range of
cytokines, with a rapid time course of induction and sub-
sequent rapid downregulation, a very significant increase in
J Mol Hist (2011) 42:137–151 149
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expression at sites of inflammation, particularly in areas
where the inflammation is acute and/or cytokines are
present at highest levels. This makes SOCS3 a potential
marker of sites at which there are significant levels of
cytokines and it may be a more stable and useful marker of
ongoing inflammation than the cytokines themselves.
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